1
|
Pivot X, Manikhas A, Shamrai V, Dzagnidze G, Soo H, Kaewkangsadan V, Petrelli F, Villanueva C, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Deforce F, Cox D. 2MO Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
2
|
Bhatnagar R, Linnane B, Herzig M, Ni Chroinin M, Cox D, Elnazir B, Segurado R, Kirwan L, Southern KW, Fitzpatrick P. Challenges faced by parents of screen-detected children with Cystic Fibrosis: The ICOS study. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac131.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Informal care is an essential component of overall care for patients, particularly those with chronic illnesses such as Cystic Fibrosis (CF). This study aims to assess the level of caregiving burden faced by parents/caregivers of children with CF (CwCF) recruited to the Irish Comparative Outcomes Study of CF (ICOS), a historical cohort study of CwCF. In July 2011, a new-born screening programme began in Ireland.
Methods
The study population includes the parents of screen-detected CwCF born between July 2011-2021. The Challenge of Living with CF-Short Form is a new, validated 15-item tool that evaluates the caregiving burden faced by parents from the child’s diagnosis until early adolescence. Comparisons based on the age of screen-detected CwCF were conducted. SPSS was used for analysis.
Results
69 parents of screen-detected CwCF responded. Fifty percent of parents of older children (aged 4-12+ years) and 35% of the parents of toddlers (0-3 years) faced moderate-high level difficulties in managing the extra expenses required for the care of their CwCF, despite all children receiving free clinical care, prescriptions and medications. A significantly greater proportion of the parents of older children than younger children experienced constant problems in managing daily oral medication routines (37% vs 13%; P = 0.039), nebulised medication routines (67.5% vs 21.4%; P = 0.003), and physiotherapy routines (57.8% vs 31.8%; P = 0.046)
Conclusions
Using the novel Challenge of living with Cystic Fibrosis-Short Form questionnaire, our findings suggest that the caregiving burden is higher for parents of older CwCF. Expenses incurred by parents of a child with a serious chronic medical condition go beyond medical care and treatment expenses.
Key messages
• The challenge of living with Cystic Fibrosis-Short Form is being used for the first time in a population setting.
• The caregiving burden was more pronounced in the parents of older CwCF.
Collapse
Affiliation(s)
- R Bhatnagar
- School of Public Health, Physiotherapy and Sports Science, University College Dublin , Dublin, Ireland
| | - B Linnane
- University Hospital Limerick , Limerick, Ireland
| | - M Herzig
- University Hospital Galway , Galway, Ireland
| | | | - D Cox
- Children’s Health Ireland at Crumlin , Dublin, Ireland
| | - B Elnazir
- Children’s Health Ireland at Tallaght , Dublin, Ireland
- Trinity College Dublin , Dublin, Ireland
| | - R Segurado
- School of Public Health, Physiotherapy and Sports Science, University College Dublin , Dublin, Ireland
| | - L Kirwan
- Cystic Fibrosis Registry , Dublin, Ireland
| | | | - P Fitzpatrick
- School of Public Health, Physiotherapy and Sports Science, University College Dublin , Dublin, Ireland
| |
Collapse
|
3
|
FitzGerald J, Lester K, O'Sullivan N, Crispie F, Lawton E, Cotter P, McNally P, Cox D. 524 Striking a BAL-NS: Combining metagenomics with culture methods shows nasal swabs to be a good proxy for bronchoalveolar lavage in microbial and pathogen surveillance. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01214-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
4
|
Calvet XS, Simon EF, Jurado PP, Unsworth A, Perez JA, Schiava M, Queen R, Fernandez SL, Pons G, Mathews I, Rushton P, Cox D, Bowey A, Henderson M, Charlton R, Ortez C, Natera D, Mallebriera CJ, Nascimento A, Manera JD. O.16 Single cell RNA sequencing study of FAPS obtained from muscle samples of DMD patients reveals new pathogenic pathways of the muscle degeneration process. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Sutton S, Hayden J, Howlett M, Davies J, Fleming A, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Quittner A, McNally P. 251 Evaluation of the Medication Electronic Monitoring Systems n adherence measurement in a real-world setting. J Cyst Fibros 2022. [PMCID: PMC9527886 DOI: 10.1016/s1569-1993(22)00941-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Lim S, Murphy S, Murphy S, Coughlan T, O'Neill D, Tierney S, Egan B, Collins D, McCarthy A, Lim SY, Smith D, Cox D, McCabe D. Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. J Neurol Sci 2022; 441:120334. [DOI: 10.1016/j.jns.2022.120334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 05/30/2022] [Accepted: 06/30/2022] [Indexed: 11/24/2022]
|
7
|
Rom M, Schott R, Pencreac'h E, Cébula H, Cox D, Bender L, Antoni D, Lhermitte B, Noel G. [Impact of NGS results on patient outcome with a multiform glioblastoma]. Cancer Radiother 2022; 26:987-993. [PMID: 35715358 DOI: 10.1016/j.canrad.2022.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 01/01/2022] [Accepted: 01/17/2022] [Indexed: 11/18/2022]
Abstract
PURPOSE Although some genetic alterations in glioblastoma (GBM) have been characterized, the prognostic value of these gene mutations is not yet established in patients treated with standard therapy. PATIENTS AND METHOD 40 patients with newly diagnosed GBM, treated between July 2017 and December 2019, and who had genomic analysis were analyzed. Next-generation sequencing techniques (NGS) were used with a panel of 26 genes. Patients were grouped according to MGMT status, the presence or absence of at least one mutated gene on the panel, and p53 expression by immunohistochemistry. RESULTS the median follow-up was 11.5 months (1.0-37). For all patients, the median duration of progression-free survival was 8 months (95% CI, 5.3-10.7) and the median overall survival (OS) was 17 months (95% CI, 7.5-26.5). Progression-free and overall survival were significantly different according to MGMT status but not according to NGS and p53 status. Three groups of patients according to different combined status could be distinguished due to significant differences in overall survival. CONCLUSION we have shown that the presence of MGMT promoter methylation is a good prognostic factor. By grouping the patients according to their MGMT, NGS and p53 status, three groups of patients could be separated according to their overall survival. However, these results must be confirmed on a larger number of patients.
Collapse
Affiliation(s)
- M Rom
- ICANS-service de radiothérapie, Institut du Cancer Strasbourg-Europe, 17, rue Albert Calmette, 67033 Strasbourg, France; Service de radiothérapie - Hôpital Calmette, No. 3, Monivong Bvld, Sangkat Sras Chok, Khan Daun Penh, Phnom Penh, Royaume du Cambodge
| | - R Schott
- ICANS-service d'oncologie médicale, Institut du Cancer Strasbourg-Europe, 17, rue Albert Calmette, 67033 Strasbourg, France
| | - E Pencreac'h
- Service de biologie, CHU Hautepierre, 1, rue Molière, 67200 Strasbourg, France
| | - H Cébula
- Service de neurochirurgie - CHU Hautepierre, 1, rue Molière, 67200 Strasbourg, France
| | - D Cox
- IRFAC, Inserm U1113, 3, avenue Molière, 67000 Strasbourg, France; Research, Development in Precision Medicine, Institut de Cancérologie Strasbourg Europe (ICANS), 17, rue Albert Calmette, 67200 Strasbourg, France
| | - L Bender
- ICANS-service d'oncologie médicale, Institut du Cancer Strasbourg-Europe, 17, rue Albert Calmette, 67033 Strasbourg, France
| | - D Antoni
- ICANS-service de radiothérapie, Institut du Cancer Strasbourg-Europe, 17, rue Albert Calmette, 67033 Strasbourg, France
| | - B Lhermitte
- Service d'anatomopathologie, CHU Hautepierre, 1, rue Molière, 67200 Strasbourg, France
| | - G Noel
- ICANS-service de radiothérapie, Institut du Cancer Strasbourg-Europe, 17, rue Albert Calmette, 67033 Strasbourg, France.
| |
Collapse
|
8
|
Sutton S, Hayden J, Howlett M, Davies J, Fleming A, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Quittner A, McNally P, Lester K. ePS6.10 A real-world study evaluating the impact of elexacaftor/tezacaftor/ivacaftor treatment on medication adherence in cystic fibrosis. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00336-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Mainz J, Fleming A, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Zagoya C, Davies J, McNally P. P043 Significant reduction in abdominal symptoms assessed with the CFAbd-Score over 6 months of elexacaftor/tezacaftor/ivacaftor (ETI) - follow-up results from Irish and British cystic fibrosis patients (RECOVER study). J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00376-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Cox D, Carr B. Late 1800s Fringe Electrotherapeutic Devices: Comparative Electrical Capabilities. Eur Psychiatry 2022. [PMCID: PMC9566499 DOI: 10.1192/j.eurpsy.2022.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Desperation for cure led to 19th century invention-- electrotherapeutic devices; replete with hyperbolic claims of cure-all, perceived ineffectiveness, and potential harm rendered the modality as quackery but were used in early brain stimulation, melancholia treatment, and cortex mapping. Here, antique devices are restored, and their electrophysiological qualities ascertained. Objectives Determine the comparative capabilities of these devices in delivering electrostimulation and compare with modern standards to understand possible electrophysiological sequelae. Methods Devices known as “medical batteries” were analyzed. Power delivery utilized a “voltaic battery”, simple circuit, and a conductor wrapped around an iron core. When the circuit is energized, the core is magnetized by direct current of the battery which induces an alternating current that electrifies probes used on the body. Due to their marked age, a common 9-volt battery was exchanged for the corrosive dry cell paste batteries. Electrical parameters were then measured. ![]()
![]()
Results
Device |
Frequency (Hz) |
Resistance (Ohms) |
Max Output (Amps) |
Min Output (Amps) |
Max Output (Volts) | Min Output (Volts) |
---|
Voltampa | 2k – 12K | 60 | 0.66 | 0.33 | 60V | 20V | J.H. Bunnell & Co.’s No. 4 D.D. | 7k-10k | 50 | 6 | 0.4 | 300V | 20V | Schall & Son
(London)b | 300-1200 | 40 | 10.5 | 2.75 | 420V | 110V |
![]()
Conclusions Devices for electrotherapeutics ranged from anemic vibrations to dangerous tetany inducing shocks. Measuring the capabilities of these devices shows the robust yields possible if the original higher capacity batteries were utilized. The reality is, cure or not, the devices were surprisingly potent. It is interesting that, albeit unrefined, efficacious doses were available before modern electrification. Disclosure No significant relationships.
Collapse
|
11
|
McNally P, Fleming A, Elnazir B, Williamson M, Cox D, Linnane B, Kirwan L, Saunders C, Tiddens H, Grassemann H, McKone E, Davies J. WS06.02 Impact of one year of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in people with cystic fibrosis in a real-world setting – the RECOVER study. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00184-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Pattison M, McKinstry C, Cox D, Boniface G, McLennan N. Platinum anniversary – 70 years of highlights and influences of the World Federation of Occupational Therapists. World Federation of Occupational Therapists Bulletin 2022. [DOI: 10.1080/14473828.2022.2052623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - C. McKinstry
- Rural Department of Allied Health, La Trobe Rural Health School, La Trobe University, Bendigo, Australia
| | - D. Cox
- University of Cumbria, Cumbria, UK
| | - G. Boniface
- Department of Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, Canada
| | - N. McLennan
- Centre for Global Security & Governance Studies, University of Aberdeen, Aberdeen, UK
| |
Collapse
|
13
|
McNally P, Davies J, Linnane B, Williamson M, Elnazir B, Short C, Saunders C, Kirwan L, Vandercorput MK, Tiddens H, Cox D. 560: Real-world impact of lumacaftor/ivacaftor on pulmonary outcomes in children aged 6 to 11 with CF. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01983-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
McNally P, Fleming A, Elnazir B, Williamson M, Cox D, Linnane B, Kirwan L, Saunders C, Tiddens H, Grassemann H, McKone E, Davies J. 564: Impact of elexacaftor/tezacaftor/ivacaftor treatment on clinical outcomes in people with CF in a real-world setting—The RECOVER trial. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01987-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Mainz J, Davies J, Fleming A, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Zagoya C, McNally P. 565: Significant reduction in abdominal symptoms assessed with CFAbd score over 4 weeks of treatment with elexacaftor/tezacaftor/ivacaftor—First results from the RECOVER study. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01988-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Earl H, Hiller L, Dunn J, Conte P, D'Amico R, Guarneri V, Joensuu H, Huttunen T, Georgoulias V, Abraham J, Cameron D, Miles D, Wardley A, Romieu G, Debled M, Faure-Mercier C, Lindman H, Fraser J, Cox D, Pivot X. LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2083] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
17
|
McGrath K, Cox D. EPS2.03 Lumacaftor-ivacaftor therapy and its impact on glucose tolerance in children with cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01010-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Cox D, Alvarez D, Bock A, Cronenberger C. AB0285 RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP PHARMACOKINETIC STUDY OF PF-06410293, AN ADALIMUMAB BIOSIMILAR, BY SUBCUTANEOUS DOSING USING A PREFILLED SYRINGE OR A PREFILLED PEN IN HEALTHY SUBJECTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Similarity in efficacy, safety, and immunogenicity (IMG) of PF-06410293 (ADL-PF), an adalimumab (ADL) biosimilar, and reference ADL sourced from the European Union (ADL-EU), by subcutaneous (SC) injection using a prefilled syringe (PFS), have been demonstrated in a randomised controlled trial in patients with rheumatoid arthritis (RA) (NCT02480153).Objectives:To determine if the pharmacokinetics (PK), safety and tolerability of ADL-PF were similar following a single SC dose by prefilled pen (PFP) or PFS in healthy subjects (NCT02572245).Methods:In this phase 1, 2-arm study, healthy subjects, aged 18–55 years, were randomised (1:1) to receive ADL-PF (40 mg, SC) in the lower abdomen or upper anterior thigh by PFS or PFP. Primary endpoints were maximum observed serum concentration (Cmax) and area under the serum concentration–time profile from time 0–2 weeks after dosing (AUC0-2wk). Safety, including injection-site reactions (ISRs), and secondary PK endpoints, were also assessed. Bioequivalence between ADL-PF administered by PFS or PFP device was demonstrated if the 90% confidence intervals (CIs) for the test/reference ratios of AUC0-2wkand Cmaxfell within the 80.00–125.00% pre-specified margin.Results:A total of 164 subjects, stratified by body weight were randomised and assigned to treatment; ADL-PF PFS (n=81) and PFP (n=83). Baseline characteristics were comparable between treatment arms. 163 subjects were included in the primary PK analysis. The concentration–time profiles were comparable between the ADL-PF PFS and PFP treatment arms, and were characterized by an increase in serum drug concentrations, with the Cmaxachieved at approximately 6-7 days, followed by a multi-phasic decline in drug concentrations. The 90% CIs for test/reference ratios of the geometric means for the primary PK parameters fell within the pre-specified margin (Table). In total, 50 and 51 treatment-emergent adverse events (AEs) were reported in 31 (38.3%) and 29 subjects (34.9%), respectively, in the ADL-PF PFS and PFP groups. One subject experienced an unrelated serious AE in the ADL-PF PFS group. Injection-site pain was similar between treatment arms at all time points, and for the 2 injection-site locations. IMG testing was limited to subjects experiencing an ISR and/or rash AE, and a matched control group, with 11 (11/15; 73.3%) and 7 (7/15; 46.7%) subjects, respectively, testing anti-drug antibody (ADA)-positive. Amongst ADA-positive subjects, a majority (12/18) also tested positive for neutralising ADAs (7/11 [63.6%] and 5/7 [71.4%] subjects, respectively).Conclusion:This study demonstrated that the PK of ADL-PF was comparable following SC administration using either a PFS or PFP device. ADL-PF by PFS or PFP injection was well tolerated by healthy subjects, with the distribution of AEs, including ISRs, being similar between treatment arms.Table.Summary of Statistical Comparisons of PK Exposure Parameters between Test and Reference Treatments (PK Analysis Set)PK parameter (units)Adjusted geometric meansRatioa,b90% CIfor ratiobADL-PF PFP (test)ADL-PF PFS (reference)Cmax(μg/mL)4.454.13107.7499.16–117.06AUC0-2wk(μg•hr/mL)11501100104.8995.76–114.89AUCT(μg•hr/mL)2040210097.2386.75 – 108.98AUC0-inf(μg•hr/mL)22002150102.2791.12 – 114.78Tmax(hr)c142 (45.4, 336)166 (47.7, 674)a(test/reference) of adjusted means.bRatios and 90% CIs are expressed as percentages.cMedian (range).ADL-PF, PF-06410293; AUC, area under the serum concentration–time profile; AUC0-2wk, AUC from time 0–2 weeks after dosing; AUCinf, AUC from time 0 extrapolated to infinity; AUCT, AUC from time 0 to the time point of the last quantifiable concentration; Cmax, maximum observed serum concentration; CI, confidence interval; h, hour(s); PK, pharmacokinetic(s); PFP, prefilled pen; PFS, prefilled syringe; Tmax, time of maximum serum concentration.Acknowledgments:Medical writing support was provided by Iain McDonald of Engage Scientific Solutions. The study was funded by Pfizer.Disclosure of Interests:Donna Cox Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Daniel Alvarez Shareholder of: Pfizer, Employee of: Pfizer, Amy Bock Shareholder of: Pfizer, Employee of: Pfizer, Carol Cronenberger Shareholder of: Pfizer, Employee of: Pfizer
Collapse
|
19
|
Butler D, Montegue T, O’Sullivan N, Cox D, McNally P. P160 Study to Evaluate the Additional Gains of Upper and Lower Lobe Sampling in children with Cystic Fibrosis (SEAGULLS): safety and microbiological yield. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30495-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
20
|
Murphy SJX, Lim ST, Kinsella JA, Tierney S, Egan B, Feeley TM, Murphy SM, Walsh RA, Collins DR, Coughlan T, O'Neill D, Harbison JA, Madhavan P, O'Neill SM, Colgan MP, Cox D, Moran N, Hamilton G, Meaney JF, McCabe DJH. Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis. J Neurol 2019; 267:168-184. [PMID: 31606758 DOI: 10.1007/s00415-019-09550-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 09/17/2019] [Accepted: 09/19/2019] [Indexed: 12/25/2022]
Abstract
BACKGROUND Assessment of 'high on-treatment platelet reactivity (HTPR)' could enhance understanding of the pathophysiology of first or recurrent vascular events in carotid stenosis patients on antiplatelet therapy. METHODS This prospective, multi-centre study assessed antiplatelet-HTPR status and its relationship with micro-emboli signals (MES) in asymptomatic vs. symptomatic ≥ 50-99% carotid stenosis. Platelet function/reactivity was assessed under 'moderately high shear stress' with the PFA-100® and 'low shear stress' with VerifyNow® and Multiplate® analysers. Bilateral 1-h transcranial Doppler ultrasound of the middle cerebral arteries classified patients as MES + ve or MES - ve. RESULTS Data from 34 asymptomatic patients were compared with 43 symptomatic patients in the 'early phase' (≤ 4 weeks) and 37 patients in the 'late phase' (≥ 3 months) after TIA/ischaemic stroke. Median daily aspirin doses were higher in early symptomatic (225 mg; P < 0.001), but not late symptomatic (75 mg; P = 0.62) vs. asymptomatic patients (75 mg). There was a lower prevalence of aspirin-HTPR in early (28.6%; P = 0.028), but not late symptomatic (38.9%; P = 0.22) compared with asymptomatic patients (56.7%) on the PFA-100®, but not on the VerifyNow® or Multiplate® (P ≤ 0.53). Early symptomatic patients had a higher prevalence of aspirin-HTPR on the PFA-100® (28.6%) vs. VerifyNow® (9.5%; P = 0.049), but not Multiplate® assays (11.9%, P = 0.10). There was no difference in aspirin-HTPR prevalence between any symptomatic vs. asymptomatic MES + ve or MES - ve subgroup. DISCUSSION Recently symptomatic moderate-severe carotid stenosis patients had a lower prevalence of aspirin-HTPR than their asymptomatic counterparts on the PFA-100®, likely related to higher aspirin doses. The prevalence of antiplatelet-HTPR was positively influenced by higher shear stress levels, but not MES status.
Collapse
Affiliation(s)
- S J X Murphy
- Department of Neurology, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Stroke Service, AMNCH/Tallaght University Hospital, Dublin, Ireland
| | - S T Lim
- Department of Neurology, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Stroke Service, AMNCH/Tallaght University Hospital, Dublin, Ireland
| | - J A Kinsella
- Department of Neurology, St Vincent's University Hospital, University College Dublin, Dublin, Ireland
| | - S Tierney
- Department of Vascular Surgery, AMNCH/Tallaght University Hospital, Dublin, Ireland
| | - B Egan
- Department of Vascular Surgery, AMNCH/Tallaght University Hospital, Dublin, Ireland
| | - T M Feeley
- Department of Vascular Surgery, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Dublin Midlands Hospital Group, Dublin, Ireland
| | - S M Murphy
- Department of Neurology, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Stroke Service, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Academic Unit of Neurology, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - R A Walsh
- Department of Neurology, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Academic Unit of Neurology, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - D R Collins
- Age-Related Health Care Department, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Stroke Service, AMNCH/Tallaght University Hospital, Dublin, Ireland
| | - T Coughlan
- Age-Related Health Care Department, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Stroke Service, AMNCH/Tallaght University Hospital, Dublin, Ireland
| | - D O'Neill
- Age-Related Health Care Department, AMNCH/Tallaght University Hospital, Dublin, Ireland.,Stroke Service, AMNCH/Tallaght University Hospital, Dublin, Ireland
| | - J A Harbison
- Department of Medicine for the Elderly/Stroke Service, St. James's Hospital/Trinity College Dublin, Dublin, Ireland
| | - P Madhavan
- Department of Vascular Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland
| | - S M O'Neill
- Department of Vascular Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland
| | - M P Colgan
- Department of Vascular Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland
| | - D Cox
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.,Irish Centre for Vascular Biology, Dublin, Ireland
| | - N Moran
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.,Irish Centre for Vascular Biology, Dublin, Ireland
| | - G Hamilton
- Department of Vascular Surgery, University Department of Surgery, Royal Free Hampstead NHS Trust, London, UK
| | - J F Meaney
- Department of Radiology, Centre for Advanced Medical Imaging, St. James's Hospital/Trinity College Dublin, Dublin, Ireland
| | - D J H McCabe
- Vascular Neurology Research Foundation, C/O Department of Neurology, The Adelaide and Meath Hospital, Dublin, Incorporating the National Children's Hospital (AMNCH)/Tallaght University Hospital, Tallaght, Dublin 24, Ireland. .,Department of Neurology, AMNCH/Tallaght University Hospital, Dublin, Ireland. .,Stroke Service, AMNCH/Tallaght University Hospital, Dublin, Ireland. .,Department of Clinical Neurosciences, Royal Free Campus, UCL Queen Square Institute of Neurology, London, UK. .,Irish Centre for Vascular Biology, Dublin, Ireland. .,Stroke Clinical Trials Network Ireland, Dublin, Ireland. .,Academic Unit of Neurology, School of Medicine, Trinity College Dublin, Dublin, Ireland.
| |
Collapse
|
21
|
Geaney S, Cox D, Hönigl-Decrinis T, Shaikhaidarov R, Kubatkin SE, Lindström T, Danilov AV, de Graaf SE. Near-Field Scanning Microwave Microscopy in the Single Photon Regime. Sci Rep 2019; 9:12539. [PMID: 31467310 PMCID: PMC6715798 DOI: 10.1038/s41598-019-48780-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Accepted: 08/07/2019] [Indexed: 11/09/2022] Open
Abstract
The microwave properties of nano-scale structures are important in a wide variety of applications in quantum technology. Here we describe a low-power cryogenic near-field scanning microwave microscope (NSMM) which maintains nano-scale dielectric contrast down to the single microwave photon regime, up to 109 times lower power than in typical NSMMs. We discuss the remaining challenges towards developing nano-scale NSMM for quantum coherent interaction with two-level systems as an enabling tool for the development of quantum technologies in the microwave regime.
Collapse
Affiliation(s)
- S Geaney
- National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, UK.
- Royal Holloway, University of London, Egham, TW20 0EX, UK.
| | - D Cox
- Advanced Technology Institute, The University of Surrey, Guildford, GU2 7XH, UK
| | - T Hönigl-Decrinis
- National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, UK
| | | | - S E Kubatkin
- Department of Microtechnology and Nanoscience, Chalmers University of Technology, SE-412 96, Göteborg, Sweden
| | - T Lindström
- National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, UK
| | - A V Danilov
- Department of Microtechnology and Nanoscience, Chalmers University of Technology, SE-412 96, Göteborg, Sweden
| | - S E de Graaf
- National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, UK.
| |
Collapse
|
22
|
Fitzpatrick P, Fitzgerald C, Ni Chroinin M, Mullane D, Herzig M, Greally P, Healy F, Mcnally P, Javadpour S, Cox D, George S, Linnane B. WS10.5 The Irish Comparative Outcome Study (ICOS): clinical outcomes at 3 years following introduction of newborn cystic fibrosis screening. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30176-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
23
|
McMacken G, Cox D, Roos A, Müller J, Whittaker R, Lochmüller H. Adrenergic agonists modulate neuromuscular junction formation in zebrafish models of human myasthenic syndromes. Neuromuscul Disord 2018. [DOI: 10.1016/s0960-8966(18)30373-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Rigby J, Cox D, Julian K. Journal peer review: a bar or bridge? An analysis of a paper's revision history and turnaround time, and the effect on citation. Scientometrics 2018; 114:1087-1105. [PMID: 29491545 PMCID: PMC5814533 DOI: 10.1007/s11192-017-2630-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Indexed: 11/02/2022]
Abstract
Journal peer review lies at the heart of academic quality control. This article explores the journal peer review process and seeks to examine how the reviewing process might itself contribute to papers, leading them to be more highly cited and to achieve greater recognition. Our work builds on previous observations and views expressed in the literature about (a) the role of actors involved in the research and publication process that suggest that peer review is inherent in the research process and (b) on the contribution reviewers themselves might make to the content and increased citation of papers. Using data from the journal peer review process of a single journal in the Social Sciences field (Business, Management and Accounting), we examine the effects of peer review on papers submitted to that journal including the effect upon citation, a novel step in the study of the outcome of peer review. Our detailed analysis suggests, contrary to initial assumptions, that it is not the time taken to revise papers but the actual number of revisions that leads to greater recognition for papers in terms of citation impact. Our study provides evidence, albeit limited to the case of a single journal, that the peer review process may constitute a form of knowledge production and is not the simple correction of errors contained in submitted papers.
Collapse
Affiliation(s)
- J Rigby
- Manchester Institute of Innovation Research, Alliance Manchester Business School, The University of Manchester, c/o Room 8.23, Harold Hankins Building, Oxford Road, Manchester, M13 9PL UK
| | - D Cox
- Manchester Institute of Innovation Research, Alliance Manchester Business School, The University of Manchester, c/o Room 8.23, Harold Hankins Building, Oxford Road, Manchester, M13 9PL UK
| | - K Julian
- Manchester Institute of Innovation Research, Alliance Manchester Business School, The University of Manchester, c/o Room 8.23, Harold Hankins Building, Oxford Road, Manchester, M13 9PL UK
| |
Collapse
|
25
|
Topf A, Azuma Y, Gorokhova S, O'Connor E, Porter A, Harris E, Evangelista T, Cox D, Lorenzoni P, McMacken G, Bartoli M, McArthur D, Magnusson O, Abicht A, Senderek J, Roos A, Abicht A, Lochmüller H. Next generation sequencing technologies in the genetic diagnosis of congenital myasthenic syndrome. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
26
|
Cox D, Blanc E, Romieu G, Rios M, Becuwe C, Jouannaud C, Chaigneau L, Arnedos M, Orfeuvre H, Petit T, Quenel Tueux N, Jacquin JP, Ferrero JM, Abadie Lacourtoisie S, Penault-Llorca F, Segura-Ferlay C, Moullet I, Bachelot T, Pivot X. SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Gandini F, Bigelow TS, Becket B, Caughman JB, Cox D, Darbos C, Gassmann T, Henderson MA, Jean O, Kajiwara K, Kobayashi N, Nazare C, Oda Y, Omori T, Purohit D, Rasmussen DA, Ronden DMS, Saibene G, Sakamoto K, Shapiro MA, Takahashi K, Temkin RJ. The EC H&CD Transmission Line for ITER. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-38] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Gandini
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - T. S. Bigelow
- U.S. ITER Project Office, ORNL, 1055 Commerce Park, Oak Ridge, Tennessee 37831
| | - B. Becket
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - J. B. Caughman
- U.S. ITER Project Office, ORNL, 1055 Commerce Park, Oak Ridge, Tennessee 37831
| | - D. Cox
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - C. Darbos
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - T. Gassmann
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - M. A. Henderson
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - O. Jean
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - K. Kajiwara
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - N. Kobayashi
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - C. Nazare
- Assystem Facilities, 23 Place de Wicklow CS 30713, 78067 Saint Quentin en Yvelines Cedex, France
| | - Y. Oda
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - T. Omori
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - D. Purohit
- ITER Organization, CS 90 046 - 13067 Saint Paul Lez Durance Cedex, France
| | - D. A. Rasmussen
- U.S. ITER Project Office, ORNL, 1055 Commerce Park, Oak Ridge, Tennessee 37831
| | - D. M. S. Ronden
- Association EURATOM-FOM, 3430 BE Nieuwegein, The Netherlands
| | - G. Saibene
- Fusion for Energy, C/Josep Pla 2, Torres Diagonal Litoral-B3, E-08019 Barcelona, Spain
| | - K. Sakamoto
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - M. A. Shapiro
- MIT Plasma Science and Fusion Center, Cambridge, Massachusetts 02139
| | - K. Takahashi
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-shi, Ibaraki 311-0193, Japan
| | - R. J. Temkin
- MIT Plasma Science and Fusion Center, Cambridge, Massachusetts 02139
| |
Collapse
|
28
|
Grabman J, Vajda Bailey K, Schmidt K, Cariou B, Vaur L, Madani S, Cox D, Gonder-Frederick L. An empirically derived short form of the Hypoglycaemia Fear Survey II. Diabet Med 2017; 34:500-504. [PMID: 27278467 DOI: 10.1111/dme.13162] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/07/2016] [Indexed: 11/30/2022]
Abstract
AIMS To develop an empirically derived short version of the Hypoglycaemia Fear Survey II that still accurately measures fear of hypoglycaemia. METHODS Item response theory methods were used to generate an 11-item version of the Hypoglycaemia Fear Survey from a sample of 487 people with Type 1 or Type 2 diabetes mellitus. Subsequently, this scale was tested on a sample of 2718 people with Type 1 or insulin-treated Type 2 diabetes taking part in DIALOG, a large observational prospective study of hypoglycaemia in France. RESULTS The short form of the Hypoglycaemia Fear Survey II matched the factor structure of the long form for respondents with both Type 1 and Type 2 diabetes, while maintaining adequate internal reliability on the total scale and all three subscales. The two forms were highly correlated on both the total scale and each subscale (Pearson's R > 0.89). CONCLUSIONS The short form of the Hypoglycaemia Fear Survey II is an important first step in more efficiently measuring fear of hypoglycaemia. Future prospective studies are needed for further validity testing and exploring the survey's applicability to different populations.
Collapse
Affiliation(s)
- J Grabman
- Behavioral Medicine Center, University of Virginia, Charlottesville, VA, USA
| | - K Vajda Bailey
- Behavioral Medicine Center, University of Virginia, Charlottesville, VA, USA
| | - K Schmidt
- Department of Psychology, University of Virginia, Charlottesville, VA, USA
| | - B Cariou
- Clinique d'Endocrinologie, l'Institut du Thorax, CHU de Nantes, Nantes, France
| | - L Vaur
- Novo Nordisk, Paris, France
| | | | - D Cox
- Behavioral Medicine Center, University of Virginia, Charlottesville, VA, USA
| | - L Gonder-Frederick
- Behavioral Medicine Center, University of Virginia, Charlottesville, VA, USA
| |
Collapse
|
29
|
Cox D, Gottschalk M, Wesseling H, Ernst A, Cooper J, Bahn S. A novel methodology to evaluate the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.1563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Rodent models of schizophrenia (SCZ) are indispensable when screening for novel treatments, but quantifying their translational relevance with the underlying human pathophysiology has proved difficult. A novel systems methodology (shown in Figure 1) was developed integrating and comparing proteomic data of anterior prefrontal cortex tissue from SCZ post-mortem brains and matched controls with data obtained from four established glutamatergic rodent models, with the aim of evaluating which of these models represent SCZ most closely. Liquid chromatography coupled tandem mass spectrometry (LC-MSE) proteomic profiling was applied comparing healthy and “disease state” in human post-mortem samples and rodent brain tissue samples. Protein-protein interaction networks were constructed from significant abundance changes and enrichment analyses enabled the identification of pathophysiological characteristics of the disorder, which were represented across all four rodent models. Subsequently, these functional domains were used for cross-species comparisons. Five functional domains such as “development and differentiation” represented across all four rodent models, were identified. It was quantified that the chronic phencyclidine (cPCP) model represented SCZ brain changes most closely for four of these functional domains, by using machine-learning techniques. This is the first study aiming to quantify which rodent model recapitulates the neuropathological features of SCZ most closely. The methodology and findings presented here support recent efforts to overcome translational hurdles of preclinical psychiatric research by associating behavioural endophenotypes with distinct biological processes.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
30
|
Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Soulie P, Jouannaud C, Bourgeois H, Pierga JY, Tennevet I, Trillet-Lenoir V, Kerbrat P, Petit T, Bachelot T, Deleuze JF, Pauporte I, Romieu G, Cox D. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.34] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Curtit E, Vincent-Salomon A, Paget-Bailly S, Romieu G, Fumoleau P, Bonnefoi H, Jouannaud C, Petit T, Darut-Jouve A, Trillet-Lenoir V, Tarpin C, Pierga JY, Rios M, Jacquin J, Bachelot T, Cox D, Deleuze JF, Pauporte I, Henriques J, Pivot X. Effects of HER2 immuno-histochemistry expression levels on survival in patients treated by trastuzumab at the adjuvant setting in the SIGNAL/PHARE prospective cohort. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Machara A, Hudlický T, Endoma-Arias M, Císařova I, Cox D. Synthesis of Nororipavine and Noroxymorphone via N- and O-Demethylation of Iron Tricarbonyl Complex of Thebaine. SYNTHESIS-STUTTGART 2016. [DOI: 10.1055/s-0035-1562345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
Machara A, Hudlický T, Endoma-Arias M, Císařova I, Cox D. Synthesis of Nororipavine and Noroxymorphone via N- and O-Demethylation of Iron Tricarbonyl Complex of Thebaine. SYNTHESIS-STUTTGART 2016. [DOI: 10.1055/s-0035-1561435] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Aleš Machara
- Department of Organic Chemistry, Faculty of Science, Charles University in Prague
| | - Tomáš Hudlický
- Department of Chemistry and Centre for Biotechnology, Brock University
| | - Mary Endoma-Arias
- Department of Chemistry and Centre for Biotechnology, Brock University
| | - Ivana Císařova
- Department of Inorganic Chemistry, Faculty of Science, Charles University in Prague
| | | |
Collapse
|
34
|
Moriarty RD, Cox A, McCall M, Smith SGJ, Cox D. Escherichia coli induces platelet aggregation in an FcγRIIa-dependent manner. J Thromb Haemost 2016; 14:797-806. [PMID: 26669970 DOI: 10.1111/jth.13226] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 11/30/2015] [Indexed: 12/20/2022]
Abstract
BACKGROUND The discovery of pathogen-recognition receptors such as Toll-like receptors on platelets has led to the emergence of the concept of platelets as important components of the host response to infection. Escherichia coli (E. coli)-mediated sepsis is a serious illness characterized by the occurrence of thrombocytopenia. Whereas there has been a wealth of research on platelet activation by Gram-positive bacteria, little is known about the mechanisms associated with Gram-negative bacteria-induced platelet activation with Gram-negative bacteria. OBJECTIVES To determine the mechanisms by which Gram-negative E. coli induces platelet aggregation. METHODS Induction of platelet aggregation with E. coli strain O157:H7 was tested in platelet-rich plasma (PRP), washed platelets, and serum depleted of complement factors. Platelet inhibitors (against αII b β3 , glycoprotein Ibα and FcγRIIa) were used. Platelet thromboxane synthesis was analyzed after E. coli stimulation. Cell binding assays were used to assess the ability of E. coli to support platelet adhesion. Trypsinization was used to determine the role of E. coli surface proteins. RESULTS AND CONCLUSION E. coli-induced aggregation in PRP was donor-dependent. E. coli O157:H7 induced aggregation with a lag time of 6.9 ± 1.3 min in an αII b β3 -dependent and FcγRIIa-dependent manner. Furthermore, this interaction was enhanced by the presence of complement, and was dependent on thromboxane synthesis. These results show E. coli to be a potent inducer of platelet aggregation.
Collapse
Affiliation(s)
- R D Moriarty
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - A Cox
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - M McCall
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - S G J Smith
- Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - D Cox
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| |
Collapse
|
35
|
Bachelot T, Lavergne E, Romieu G, Rios M, Heudel PE, Roemer-Becuwe C, Jouannaud C, Tredan O, Chaigneau L, Arnedos M, Orfeuvre H, Petit T, Quenel-Tueux N, Jacquin JP, Ferrero JM, Moullet I, Abadie-Lacourtoisie S, Penault-Llorca F, Blanc E, Cox D. Abstract P1-08-06: SToRM: A prospective clinical trial of 1502 metastatic breast cancer (mBC) patients with detail of clinical presentation, molecular subtype, treatment modalities, prognosis and GWAS genotyping. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-08-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Due to better molecular classification and new treatment options, epidemiology and prognosis of mBC is rapidly changing. Clinical data extracted from randomized studies are only relevant to specific subpopulations and retrospective studies are prone to selection bias. SToRM is a prospective clinical trial that aims to create a cohort of 1500 mBC patients, with the ultimate goal of identifying germ line polymorphisms associated with prognosis of breast cancer (BC) and response to treatment in the metastatic phase.
Material and methods: Any newly (within 1 year) diagnosed mBC patients were eligible. Whole blood samples were drawn and germline DNA extracted for genetic analysis. Extensive epidemiologic data, disease history from primary diagnosis to metastatic spread, pathological characteristics and ER, PR and HER2 status were collected. Patients are prospectively followed until death. Genotyping using the HumanCoreExome chipset from Illumina is currently underway and will be completed in early summer 2015.
Results: 1502 patients were included from March 2012 to May 2014 from 71 French institutions. Median age at metastatic relapse was 60 years (range 26-93). Median time from primary diagnosis to metastatic relapse was 30 months (range 0-473) with 24% of patients already metastatic at initial diagnosis. 78% of patients were ER+, 18% were HER2+ and only 16% were triple negative. Molecular subtype classification derived from pathological data following St Gallen consensus recommendations is presented below:
n (%)Luminal A like261 (22.2%)Luminal B like HER2 negative476 (40.5%)Luminal B like HER2 positive134 (11.4%)HER2 positive non Luminal (ER-)111 (9.5%)Triple negative193 (16.4%)Missing data327
64% of the patients had received previous adjuvant treatment, among which 81% received adjuvant chemotherapy and 9% trastuzumab.
At metastatic relapse, loco-regional progression, liver, lung and bone metastasis were documented in 301 (20%), 494 (33%), 410 (27%) and 1017 (68%) patients respectively. 313 patients (21%) had bone only metastatic disease. First line treatment included: chemotherapy (71%), endocrine therapy (50%) and anti-HER2 treatments (17%). Survival data will be presented at the meeting.
Conclusion: Despite a theoretically better prognosis and widespread use of adjuvant hormonal treatment, ER+/HER2- breast cancer still account for more than 60% of mBC. The proportion of patients with HER2+ disease (18%) and triple negative disease (16%) is consistent with percentages observed in early BC populations. In comparison with a cohort of "cured", localized cancer, such as the SIGNAL/PHARE study, GWAS analysis will allow for the identification of genetic polymorphisms correlated with treatment resistance. Fundamentally, such variants will provide insight into the molecular mechanisms responsible for host-genetic influence on BC progression. From a clinical perspective, genetic variants that predispose to metastatic disease can serve as stratification variables in future clinical trials, particularly as the development of new treatment options for resistant BC is needed.
Citation Format: Bachelot T, Lavergne E, Romieu G, Rios M, Heudel P-E, Roemer-Becuwe C, Jouannaud C, Tredan O, Chaigneau L, Arnedos M, Orfeuvre H, Petit T, Quenel-Tueux N, Jacquin J-P, Ferrero J-M, Moullet I, Abadie-Lacourtoisie S, Penault-Llorca F, Blanc E, Cox D. SToRM: A prospective clinical trial of 1502 metastatic breast cancer (mBC) patients with detail of clinical presentation, molecular subtype, treatment modalities, prognosis and GWAS genotyping. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-08-06.
Collapse
Affiliation(s)
- T Bachelot
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - E Lavergne
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - G Romieu
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - M Rios
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - P-E Heudel
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - C Roemer-Becuwe
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - C Jouannaud
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - O Tredan
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - L Chaigneau
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - M Arnedos
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - H Orfeuvre
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - T Petit
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - N Quenel-Tueux
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - J-P Jacquin
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - J-M Ferrero
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - I Moullet
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - S Abadie-Lacourtoisie
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - F Penault-Llorca
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - E Blanc
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - D Cox
- Centre Leon Berard, Lyon cedex 08, France; Institut Régional du Cancer Montpellier (ICM), Montpellier Cedex, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy Cedex, France; Centre d'Oncologie de Gentilly, Nancy, France; Institut Jean Godinot, Reims Cedex, France; CHU de Besançon - Hopital Jean Minjoz, Besançon, France; Gustave Roussy Cancer Campus, Villejuif Cedex, France; Hôpital Fleyriat - Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse Cedex, France; Centre Paul Strauss, Strasbourg Cedex, France; Institut Bergonié, Bordeaux Cedex, France; Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France; Centre Antoine Lacassagne, Nice Cedex 02, France; Clinique de la Sauvegarde, Lyon, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers Cedex 09, France; Centre Jean Perrin, Clermont-Ferrand Cedex, France
| |
Collapse
|
36
|
Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier AS, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. Abstract P6-07-13: New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-07-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2-positive (HER2+) breast cancers are defined by the amplification and/or overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12. Although anti-HER2 targeted therapies have greatly improved treatment of HER2+ breast cancer, the magnitude of benefit varies widely between patients. Deciphering the genomic and genetic heterogeneity of HER2+ breast cancer may provide a basis to better understand their natural history, opening new avenues of treatment.
Methods: As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 HER2+ primary invasive carcinomas, and a genome wide association study (GWAS) of over 9.836 breast cancer patients in the prospective SIGNAL/PHARE cohort (NCT00381901 – RECF1098).
Results: Using WGS data we precisely delineate the ERBB2 amplicon as a 106 kb region involving six genes and show that the amplification mechanism was consistent with breakage-fusion-bridge (BFB) cycles. Four RNA expression-based groups were identified, displaying specific genomic alterations in terms of amplification, rearrangements and mutations. On other hand, GWAS analyses failed to identify any constitutional variants associated with HER2 amplification.
Discussion: By combining whole genome sequencing and expression analysis, we provide evidence showing that HER2+ tumours display considerably more molecular heterogeneity than previously reported. These results are reinforced with the lack of association between any genetic variants and HER2 amplification from GWAS analyses. Taken as a whole, these results suggest that HER2+ breast cancers do not represent per se a homogeneous subtype, but are distributed along the whole breast cancer spectrum, from ER-positive luminal to ER-negative basal phenotype. Genome alterations present in HER2+ tumors are in accordance with these phenotypes, and it is likely that the HER2 amplification is a secondary event in the course of tumorigenesis, not favored by any particular constitutional or somatic genetic variants.
Citation Format: Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier A-S, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-13.
Collapse
Affiliation(s)
- A Vincent-Salomon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Ferrari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - X Pivot
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Macgrogan
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Arnould
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Treilleux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Romieux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A-S Sertier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - E Thomas
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Tonon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - S Boyault
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - J Kielbassa
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - V Letexier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Pauporte
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Birbaum
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - P Saintigny
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Cox
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Viari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| |
Collapse
|
37
|
Chainani-Wu N, Madden E, Cox D, Sroussi H, Epstein J, Silverman S. Toluidine blue aids in detection of dysplasia and carcinoma in suspicious oral lesions. Oral Dis 2015; 21:879-85. [PMID: 26173924 DOI: 10.1111/odi.12358] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Revised: 07/01/2015] [Accepted: 07/05/2015] [Indexed: 11/28/2022]
Abstract
OBJECTIVES Accurate clinical identification of 'higher-risk' oral premalignant lesions or 'higher-risk' areas within lesions is important. Assessment methods that predict their presence have great utility. SUBJECTS AND METHODS A cross-sectional, observational study enrolled a consecutive sample of consenting patients diagnosed with oral leukoplakia, erythroleukoplakia, or erythroplakia. Medical history, visual oral examination, ViziLite(®) examination, toluidine blue staining (TBlue(®) ), and finally a biopsy were completed in a single clinic visit. Seventy-seven of 100 examined lesions in 43 patients were biopsied. Sensitivity, specificity, and positive and negative predictive values were computed for visual examination, ViziLite(®) , and TBlue(®) using biopsy results as the gold standard. RESULTS The sensitivity of TBlue(®) in detecting high-risk lesions (carcinoma in situ or carcinoma) was 94 (71-100, P < 0.0003) and specificity 45 (32-58, P < 0.53), while for carcinoma, sensitivity was 100 (54-100, P < 0.032) and specificity 39 (28-52, P < 0.097). The results of ViziLite(®) testing either by itself or in combination with the information from toluidine blue testing revealed low sensitivity for the detection of high-risk lesions. CONCLUSIONS Clinical examination of leukoplakia, erythroplakia, or erythroleukoplakia lesions combined with toluidine blue staining may aid in the identification of severe dysplasia (carcinoma in situ) or carcinoma. This may help in determining whether, when, and where (the site within a lesion) a biopsy should be taken.
Collapse
Affiliation(s)
- N Chainani-Wu
- Private practice in oral Medicine, Mountain View, CA, USA
| | - E Madden
- Northern California Institute for Research and Education (NCIRE), San Francisco, CA, USA
| | - D Cox
- Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA, USA
| | - H Sroussi
- College of Dentistry at the University of Illinois in Chicago, Chicago, IL, USA
| | - J Epstein
- Cedars-Sinai Medical Center, Los Angeles, CA, USA.,City of Hope National Medical Center, Duarte, CA, USA
| | - S Silverman
- University of California, San Francisco, CA, USA
| |
Collapse
|
38
|
Ball G, Aljabar P, Arichi T, Tusor N, Cox D, Merchant N, Nongena P, Hajnal JV, Edwards AD, Counsell SJ. Machine-learning to characterise neonatal functional connectivity in the preterm brain. Neuroimage 2015; 124:267-275. [PMID: 26341027 PMCID: PMC4655920 DOI: 10.1016/j.neuroimage.2015.08.055] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Revised: 07/22/2015] [Accepted: 08/25/2015] [Indexed: 12/14/2022] Open
Abstract
Brain development is adversely affected by preterm birth. Magnetic resonance image analysis has revealed a complex fusion of structural alterations across all tissue compartments that are apparent by term-equivalent age, persistent into adolescence and adulthood, and associated with wide-ranging neurodevelopment disorders. Although functional MRI has revealed the relatively advanced organisational state of the neonatal brain, the full extent and nature of functional disruptions following preterm birth remain unclear. In this study, we apply machine-learning methods to compare whole-brain functional connectivity in preterm infants at term-equivalent age and healthy term-born neonates in order to test the hypothesis that preterm birth results in specific alterations to functional connectivity by term-equivalent age. Functional connectivity networks were estimated in 105 preterm infants and 26 term controls using group-independent component analysis and a graphical lasso model. A random forest–based feature selection method was used to identify discriminative edges within each network and a nonlinear support vector machine was used to classify subjects based on functional connectivity alone. We achieved 80% cross-validated classification accuracy informed by a small set of discriminative edges. These edges connected a number of functional nodes in subcortical and cortical grey matter, and most were stronger in term neonates compared to those born preterm. Half of the discriminative edges connected one or more nodes within the basal ganglia. These results demonstrate that functional connectivity in the preterm brain is significantly altered by term-equivalent age, confirming previous reports of altered connectivity between subcortical structures and higher-level association cortex following preterm birth. Robust classification of preterm and term-born neonates using functional connectivity patterns. Discriminative pattern of alterations in basal ganglia and frontal connections. Reflects system-wide disruption of subcortical–cortical connections following preterm birth.
Collapse
Affiliation(s)
- G Ball
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - P Aljabar
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - T Arichi
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - N Tusor
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - D Cox
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - N Merchant
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - P Nongena
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - J V Hajnal
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| | - A D Edwards
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom.
| | - S J Counsell
- Centre for the Developing Brain, Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom
| |
Collapse
|
39
|
Hudlicky T, Machara A, Werner L, Leisch H, Carroll R, Adams D, Haque D, Cox D. Synthesis of Naltrexone and (R)-Methylnaltrexone from Oripavine via Direct Oxidation of Its Quaternary Salts. Synlett 2015. [DOI: 10.1055/s-0034-1378808] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
| | - Ales Machara
- Faculty of Science, Charles University in Prague
| | - Lukas Werner
- Chemistry Department and Centre for Biotechnology
| | | | | | - David Adams
- Chemistry Department and Centre for Biotechnology
| | - D. Haque
- Chemistry Department and Centre for Biotechnology
| | - D. Cox
- Noramco, Inc., 503 Carr Road, Suite 200
| |
Collapse
|
40
|
Kolokythas A, Park S, Schlieve T, Pytynia K, Cox D. Squamous cell carcinoma of the oral tongue: histopathological parameters associated with outcome. Int J Oral Maxillofac Surg 2015; 44:1069-74. [PMID: 26055524 DOI: 10.1016/j.ijom.2015.01.027] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Revised: 01/05/2015] [Accepted: 01/12/2015] [Indexed: 12/26/2022]
Abstract
The purpose of this study was to investigate the applicability of the histological risk assessment model proposed by Brandwein-Gensler et al. in a cohort of oral tongue squamous cell carcinoma (OTSCC) patients treated with definitive surgery. We also examined the impact of additional histopathological features on disease acceleration. The cases of 49 OTSCC patients attending our institution between 1995 and 2009, who underwent definitive surgical resection followed by adjunct chemoradiotherapy when indicated, were reviewed retrospectively. Surgical resection specimens and complete clinical and demographic data were available for these patients; follow-up was at least 6 months. In this cohort we only identified a correlation between gender and the histopathological risk model score (P<0.001). With regard to clinical and demographic data, histopathological parameters, and disease status at last follow-up, we identified significant correlations between disease status and (1) grade of differentiation (P=0.0086), and (2) keratin score (P=0.026). We found no significant correlations between the histopathological risk assessment model and disease progression or outcomes, with the exception of gender (P<0.0001). Grade of differentiation, keratin score, and the lymphocytic host response significantly impacted disease acceleration. For OTSCC, it appears that clinical characteristics of the tumour as well as histopathological markers play an important role in the outcome. Efforts towards identifying predictive markers should be continued, especially by sub-site of the oral cavity.
Collapse
Affiliation(s)
- A Kolokythas
- Department of Oral and Maxillofacial Surgery, University of Illinois at Chicago, Chicago, IL, USA.
| | - S Park
- Department of Pathology, University of Pittsburg Medical Center, Pittsburg, PA, USA
| | - T Schlieve
- Department of Oral and Maxillofacial Surgery, University of Illinois at Chicago, Chicago, IL, USA
| | - K Pytynia
- Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Regional Care Center Katy, Houston, TX, USA
| | - D Cox
- Department of Dental Practice, Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA, USA
| |
Collapse
|
41
|
Tan ZB, Cox D, Nieminen T, Lähteenmäki P, Golubev D, Lesovik GB, Hakonen PJ. Cooper pair splitting by means of graphene quantum dots. Phys Rev Lett 2015; 114:096602. [PMID: 25793837 DOI: 10.1103/physrevlett.114.096602] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Indexed: 05/21/2023]
Abstract
A split Cooper pair is a natural source for entangled electrons which is a basic ingredient for quantum information in the solid state. We report an experiment on a superconductor-graphene double quantum dot (QD) system, in which we observe Cooper pair splitting (CPS) up to a CPS efficiency of ∼10%. With bias on both QDs, we are able to detect a positive conductance correlation across the two distinctly decoupled QDs. Furthermore, with bias only on one QD, CPS and elastic cotunneling can be distinguished by tuning the energy levels of the QDs to be asymmetric or symmetric with respect to the Fermi level in the superconductor.
Collapse
Affiliation(s)
- Z B Tan
- Low Temperature Laboratory, Department of Applied Physics, Aalto University, P.O. Box 15100, FI-00076 Aalto, Finland
| | - D Cox
- Low Temperature Laboratory, Department of Applied Physics, Aalto University, P.O. Box 15100, FI-00076 Aalto, Finland
| | - T Nieminen
- Low Temperature Laboratory, Department of Applied Physics, Aalto University, P.O. Box 15100, FI-00076 Aalto, Finland
| | - P Lähteenmäki
- Low Temperature Laboratory, Department of Applied Physics, Aalto University, P.O. Box 15100, FI-00076 Aalto, Finland
| | - D Golubev
- Low Temperature Laboratory, Department of Applied Physics, Aalto University, P.O. Box 15100, FI-00076 Aalto, Finland
| | - G B Lesovik
- L.D. Landau Institute for Theoretical Physics RAS, Chernogolovka, 142432 Moscow Region, Russia
| | - P J Hakonen
- Low Temperature Laboratory, Department of Applied Physics, Aalto University, P.O. Box 15100, FI-00076 Aalto, Finland
| |
Collapse
|
42
|
Cox D, Powell A. PB.12. Audit and root-cause analysis of classification 2 and 3 interval cancers. Breast Cancer Res 2014. [PMCID: PMC4243078 DOI: 10.1186/bcr3703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
43
|
Knudsen E, Cox D, Franco J, Frankel A, Haley B, Witkiewicz A. Targeting CDK4/6 in Her2 Positive Breast Cancer: Therapeutic Effect, Markers, and Combination Strategies. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu069.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Forsberg U, Rudolph D, Golubev P, Sarmiento L, Yakushev A, Andersson LL, Nitto AD, Düllmann C, Gates J, Gregorich K, Gross C, Heßberger F, Herzberg RD, Khuyagbaatar J, Kratz J, Rykaczewski K, Schädel M, Åberg S, Ackermann D, Block M, Brand H, Carlsson B, Cox D, Derkx X, Eberhardt K, Even J, Fahlander C, Gerl J, Jäger E, Kindler B, Krier J, Kojouharov I, Kurz N, Lommel B, Mistry A, Mokry C, Nitsche H, Omtvedt J, Papadakis P, Ragnarsson I, Runke J, Schaffner H, Schausten B, Thörle-Pospiech P, Torres T, Traut T, Trautmann N, Türler A, Ward A, Ward D, Wiehl AN. Spectroscopic Tools Applied to Element Z = 115 Decay Chains. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146602036] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
45
|
Dranitsaris G, Beegle N, Kalberer T, Blau S, Cox D, Faria C. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Pharm Pract 2014; 21:170-7. [DOI: 10.1177/1078155214525369] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background Capecitabine (C), gemcitabine (G), and vinorelbine (V) are commonly used as single agents in patients with metastatic breast cancer. Eribulin (E) is one of the most recent cytotoxic agents to gain regulatory approval for metastatic breast cancer in the United States as a single agent. EMBRACE – a large randomized trial demonstrated the safety and overall survival benefit of eribulin in heavily pretreated metastatic breast cancer patients compared to treatment of physician's choice. In this analysis, toxicity and the associated health care resource use were compared between the four agents in a sample of metastatic breast cancer patients treated in a US community oncology setting. Methods This study identified 411 patients (C=144, G=81, V=96, and E=90) who were treated in 19 community oncology clinics over the preceding two-year period. Data collection included baseline patient and disease characteristics, duration of therapy, use of supportive care drugs, type of dose limiting toxicities, and their impact on overall health care resource use. Results The median lines of therapy for C, G, V, and E were second, third, third, and fourth, respectively. Patients were comparable with respect to baseline comorbidities, performance status, serum creatinine, hemoglobin, neutrophil, and platelet counts. The proportion reporting at least one adverse event (any grade) with C, G, V, and E was 45%, 65%, 75%, and 63%. The most commonly reported toxicities (regardless of grade) for C, G, and V were diarrhea (19.4%), anemia (34.6%), and neutropenia (50.0%), respectively. The most common toxicity for E was neutropenia (32.2%). Overall, 5.6%, 19.8%, 22.9%, and 22.2% of patients receiving C, G, V, and E required at least one medical intervention to manage a toxic event. Toxicity was the cause of treatment discontinuation in 25.7%, 8.6%, 11.5%, and 8.9% of C, G, V, and E patients, respectively. The primary cause for treatment discontinuation in all four cohorts was disease progression. Conclusions Eribulin demonstrated a comparable patient safety profile to gemcitabine and vinorelbine, even when administered after three lines of prior therapies. Capecitabine was generally used in earlier lines, had less neutropenia and anemia, but more treatment discontinuations due to toxicity.
Collapse
Affiliation(s)
| | - N Beegle
- Cancer Clinics of Excellence, Greenwood Village, CO, USA
| | - T Kalberer
- Cancer Clinics of Excellence, Greenwood Village, CO, USA
| | - S Blau
- Cancer Clinics of Excellence, Greenwood Village, CO, USA
| | - D Cox
- Eisai Inc., Woodcliff Lake, NJ, USA
| | - C Faria
- Eisai Inc., Woodcliff Lake, NJ, USA
| |
Collapse
|
46
|
de Jong S, Barker K, Cox D, Sveinsdottir T, Van den Besselaar P. Understanding societal impact through productive interactions: ICT research as a case. Research Evaluation 2014. [DOI: 10.1093/reseval/rvu001] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
47
|
McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song J, Rege J, Cox D, Vahdat L. Abstract P3-13-05: Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-13-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eribulin mesylate is a novel nontaxane microtubule dynamics inhibitor that is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least two chemotherapeutic regimens for MBC. We present final data from a phase 2 study that evaluated the efficacy and safety of eribulin as first-line therapy for HER2-negative (HER2-) MBC.
Methods: Patients with measureable HER2- locally recurrent or MBC with ≥12 months since prior neoadjuvant or adjuvant chemotherapy received eribulin mesylate 1.4 mg/m2 IV on days 1 and 8 of each 3-week cycle. Endpoints included objective response rate (ORR) (primary), safety, progression-free survival (PFS), time to response (TTR), and duration of response (DOR). Tumor assessments were conducted every 6 weeks for the first 6 cycles and every 6-12 weeks thereafter per RECIST 1.1.
Results: Fifty-six patients enrolled and received eribulin. Patients had a median age of 56 years (range 31-85); 32 (57%) had an ECOG status of 0; 17 (30%) had de novo stage IV; 33 (59%) had prior (neo)adjuvant therapy, including anthracycline and/or taxane (A/T) chemotherapy. Thirty-nine patients (70%) had visceral disease (45% liver, 32% lung); 41(73%) had estrogen receptor-positive (ER+) disease and 12 (21%) had triple negative (TN) disease. Thirty-two patients (57%) completed at least 6 cycles of treatment; among the 24 patients who completed fewer than 6 cycles, reasons for not completing were progressive disease (PD; n = 18), adverse events (AEs; n = 3) and patient choice (n = 3). The median number of cycles delivered was 7 (range 1-39); 6 patients (11%) received treatment for ≥12 months. Overall ORR was 27%, with median TTR of 1.4 months and median DOR of 7.4 months; stable disease (SD) rate was 48% (Table 1). Median PFS was 6.8 months. Thirty-five patients (63%) had grade 3/4 treatment-related AEs (Table 2). Treatment-related serious AEs occurred in 5 (9%) patients: neutropenia (5%), febrile neutropenia (5%), and leukopenia (2%).
Conclusions: The results of this study suggest that first-line eribulin has antitumor activity in ER+/HER2- and TN MBC with safety consistent with the known profile. Further exploration of this treatment as part of earlier lines of breast cancer therapy, including neo/adjuvant, is warranted.
Table 1. Summary of EfficacyEfficacyEribulin-treated patients N = 56ORR, n (%)15 (27)CR0PR15 (27)SD27 (48)PD12 (21)Clinical benefit rate (ORR + ≥6 mo SD)27 (48)Median months (95% CI) TTR1.4 (1.2, 2.7)DOR7.4 (4.7, NE)PFS6.8 (4.4, 7.4)NE, not estimable
Table 2. Treatment-Related AEsAE (N = 56)All events (%)Grade 3/4 (%)Leading to study drug withdrawal1111Leading to dose reduction3427Common AEs (≥25%) Alopecia820Neutropenia7050Fatigue572Peripheral neuropathy5420Nausea460Anemia364Leukopenia3018Constipation270
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-13-05.
Collapse
Affiliation(s)
- K McIntyre
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - J O'Shaughnessy
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - L Schwartzberg
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - S Glück
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - E Berrak
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - J Song
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - J Rege
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - D Cox
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - L Vahdat
- Texas Oncology-Dallas Presbyterian Hospital US Oncology, Dallas, TX; Texas Oncology Baylor-Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| |
Collapse
|
48
|
Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Rege J, Cox D, Vahdat L. Abstract P4-12-12: Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, has been approved for patients with metastatic breast cancer (MBC) who have previously received ≥2 chemotherapeutic regimens for MBC. We present final data from a phase 2 study that evaluated efficacy and safety of eribulin + trastuzumab as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2 positive (HER2+) BC.
Methods: Patients received eribulin mesylate at 1.4 mg/m2 IV on days 1 and 8 of each 21-day cycle and an initial trastuzumab dose of 8 mg/kg IV on day 1, followed by 6 mg/kg on day 1 of each subsequent cycle. Endpoints include objective response rate (ORR), safety, progression-free survival (PFS), time to response (TTR), and duration of response (DOR). Tumor assessments were conducted every 6 weeks for the first 6 cycles and every 6-12 weeks thereafter per RECIST 1.1.
Results: Fifty-two patients with a median age of 60 years (range 31- 81) were treated; 96% had stage IV disease, 73% had visceral disease, and 48% had liver metastases. Thirty one patients had prior neo/adjuvant chemotherapy (11 had prior anthracycline, and 22 had prior taxane). Patients received a median of 10(0, 33) cycles of eribulin and 11(1, 31) cycles of trastuzumab. ORR was 67% with median TTR of 1.3 months and PFS of 11.5 months (Table). The most common (>5%) Grade 3/4 treatment related treatment emergent (TRTE) AEs were neutropenia (n = 20; 38.5%), peripheral neuropathy (n = 14; 26.9%) and febrile neutropenia (n = 4; 7.7%). Serious TRTE AEs occurred in 14 patients and included neutropenia (n = 9; 17.3%), febrile neutropenia (n = 4; 7.7%), and peripheral neuropathy (n = 3; 5.8%). Reasons for discontinuation were AEs (n = 7) and PD (n = 22).
Table. Summary of Efficacy EndpointsEfficacy EndpointsEribulin/Trastuzumab N = 52Objective Response Rate, n (%)35 (67)- Complete Response (CR)2 (4)- Partial Response (PR)33 (64)Stable Disease (SD)15 (29)Progressive Disease (PD)1 (2)Not Evaluable1 (2)Overall Clinical Benefit Rate, n (%)42 (81)Time to First Objective Response, median months (95% CI)1.3 (1.2, 1.4)Duration of Objective Response, median months (95% CI)a11.1 (6.5, 17.8)Progression-Free Survival, median months (95% CI)11.5 (7.3, 13.5)Duration of Stable Disease, median months (95% CI)7.1 (5.2, 13.5)Clinical Benefit Rate = ORR+ ≥6 mo SD; an = 35
Conclusions: This study suggests that the combination of eribulin + trastuzumab first-line therapy for locally recurrent or metastatic HER2+ BC has an acceptable safety profile and results in considerable tumor response with a long DOR. Additional larger studies with this combination are warranted.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-12.
Collapse
Affiliation(s)
- S Wilks
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - S Puhalla
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - J O'Shaughnessy
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - L Schwartzberg
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - E Berrak
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - J Song
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - J Rege
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - D Cox
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| | - L Vahdat
- US Oncology - Cancer Care Centers of South Texas, San Antonio, TX; Magee Womens Hospital, Pittsburgh, PA; Texas Oncology-Baylor Charles A. Sammons Cancer Center US Oncology, Dallas, TX; The West Clinic, Memphis, TN; Eisai Inc., Woodcliff Lake, NJ; Weill Cornell Medical College, New York, NY
| |
Collapse
|
49
|
Khan H, Meraj S, Wilbraham A, Cox D, Bhatt R, Yates J, Waldron J, Powell A. PB.43: Review of the determinants of poor screening uptake at City, Sandwell and Walsall Breast Screening Units and the steps taken to improve attendance. Breast Cancer Res 2013. [PMCID: PMC3980272 DOI: 10.1186/bcr3543] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
50
|
Rudolph D, Forsberg U, Golubev P, Sarmiento LG, Yakushev A, Andersson LL, Di Nitto A, Düllmann CE, Gates JM, Gregorich KE, Gross CJ, Heßberger FP, Herzberg RD, Khuyagbaatar J, Kratz JV, Rykaczewski K, Schädel M, Åberg S, Ackermann D, Block M, Brand H, Carlsson BG, Cox D, Derkx X, Eberhardt K, Even J, Fahlander C, Gerl J, Jäger E, Kindler B, Krier J, Kojouharov I, Kurz N, Lommel B, Mistry A, Mokry C, Nitsche H, Omtvedt JP, Papadakis P, Ragnarsson I, Runke J, Schaffner H, Schausten B, Thörle-Pospiech P, Torres T, Traut T, Trautmann N, Türler A, Ward A, Ward DE, Wiehl N. Spectroscopy of element 115 decay chains. Phys Rev Lett 2013; 111:112502. [PMID: 24074079 DOI: 10.1103/physrevlett.111.112502] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Indexed: 06/02/2023]
Abstract
A high-resolution α, x-ray, and γ-ray coincidence spectroscopy experiment was conducted at the GSI Helmholtzzentrum für Schwerionenforschung. Thirty correlated α-decay chains were detected following the fusion-evaporation reaction 48Ca + 243Am. The observations are consistent with previous assignments of similar decay chains to originate from element Z=115. For the first time, precise spectroscopy allows the derivation of excitation schemes of isotopes along the decay chains starting with elements Z>112. Comprehensive Monte Carlo simulations accompany the data analysis. Nuclear structure models provide a first level interpretation.
Collapse
|